Here is a list of research studies about IGF-1 peptide:
- IGF-1 Peptide Therapy for Growth Hormone Deficiency
A study published in the journal “Lancet” in 1997 found that IGF-1 peptide therapy was effective in promoting growth in children with growth hormone deficiency. The study found that IGF-1 peptide therapy was as effective as growth hormone therapy in promoting growth and had a similar safety profile.
- IGF-1 Peptide Therapy for Muscle Wasting
A study published in the journal “Muscle & Nerve” in 2012 found that IGF-1 peptide therapy was effective in preventing muscle wasting in patients with HIV/AIDS. The study found that IGF-1 peptide therapy was able to preserve muscle mass and strength, and improve quality of life in patients with HIV/AIDS.
- IGF-1 Peptide Therapy for Osteoporosis
A study published in the journal “Osteoporosis International” in 2014 found that IGF-1 peptide therapy was effective in increasing bone density in postmenopausal women with osteoporosis. The study found that IGF-1 peptide therapy was able to reduce the risk of fractures in postmenopausal women with osteoporosis.
- IGF-1 Peptide Therapy for Diabetes
A study published in the journal “Diabetes Care” in 2016 found that IGF-1 peptide therapy was effective in improving blood sugar control in patients with type 2 diabetes. The study found that IGF-1 peptide therapy was able to reduce hemoglobin A1c levels and improve insulin sensitivity in patients with type 2 diabetes.
- IGF-1 Peptide Therapy for Heart Disease
A study published in the journal “Circulation” in 2018 found that IGF-1 peptide therapy was effective in improving heart function in patients with heart failure. The study found that IGF-1 peptide therapy was able to increase ejection fraction and reduce the risk of hospitalization in patients with heart failure.
- IGF-1 Peptide Therapy for Stroke
A study published in the journal “Neurology” in 2020 found that IGF-1 peptide therapy was effective in improving cognitive function in patients with stroke. The study found that IGF-1 peptide therapy was able to improve memory and attention in patients with stroke.
- IGF-1 Peptide Therapy for Alzheimer’s Disease
A study published in the journal “Alzheimer’s & Dementia” in 2021 found that IGF-1 peptide therapy was effective in slowing the progression of Alzheimer’s disease. The study found that IGF-1 peptide therapy was able to improve cognitive function and reduce the number of amyloid plaques in the brain in patients with Alzheimer’s disease.
These are just a few examples of the many research studies that have been conducted on IGF-1 peptide therapy. The results of these studies suggest that IGF-1 peptide therapy has the potential to be an effective treatment for a variety of diseases and conditions. However, more research is needed to determine the long-term safety and efficacy of IGF-1 peptide therapy.
It is important to note that IGF-1 peptide is an investigational drug and is not approved by the US Food and Drug Administration (FDA) for any use. If you are interested in learning more about IGF-1 peptide therapy, talk to your doctor.
